CA2978828A1 - 7-(morpholin-4-yl)pyrazole[1,5-a]pyrimidine derivatives which are useful for the treatment of immune or inflammatory diseases or cancer - Google Patents

7-(morpholin-4-yl)pyrazole[1,5-a]pyrimidine derivatives which are useful for the treatment of immune or inflammatory diseases or cancer Download PDF

Info

Publication number
CA2978828A1
CA2978828A1 CA2978828A CA2978828A CA2978828A1 CA 2978828 A1 CA2978828 A1 CA 2978828A1 CA 2978828 A CA2978828 A CA 2978828A CA 2978828 A CA2978828 A CA 2978828A CA 2978828 A1 CA2978828 A1 CA 2978828A1
Authority
CA
Canada
Prior art keywords
alkyl
compound
formula
morpholin
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA2978828A
Other languages
English (en)
French (fr)
Inventor
Barbara DYMEK
Marcin ZAGOZDA
Maciej Wieczorek
Krzysztof DUBIEL
Aleksandra Stanczak
Daria ZDZALIK
Pawel GUNERKA
Mariola SEKULAR
Maciej DZIACHAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celon Pharma SA
Original Assignee
Celon Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celon Pharma SA filed Critical Celon Pharma SA
Publication of CA2978828A1 publication Critical patent/CA2978828A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA2978828A 2015-04-02 2016-03-30 7-(morpholin-4-yl)pyrazole[1,5-a]pyrimidine derivatives which are useful for the treatment of immune or inflammatory diseases or cancer Pending CA2978828A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PL411864A PL236355B1 (pl) 2015-04-02 2015-04-02 Pochodne 7-(morfolin-4-ylo)pirazolo[1,5-α]pirymidyny jako inhibitory kinazy PI3
PL411864 2015-04-02
PCT/IB2016/051792 WO2016157091A1 (en) 2015-04-02 2016-03-30 7-(morpholin-4-yl)pyrazole[1,5-a]pyrimidine derivatives which are useful for the treatment of immune or inflammatory diseases or cancer

Publications (1)

Publication Number Publication Date
CA2978828A1 true CA2978828A1 (en) 2016-10-06

Family

ID=55650626

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2978828A Pending CA2978828A1 (en) 2015-04-02 2016-03-30 7-(morpholin-4-yl)pyrazole[1,5-a]pyrimidine derivatives which are useful for the treatment of immune or inflammatory diseases or cancer

Country Status (18)

Country Link
US (1) US10138247B2 (https=)
EP (1) EP3277687B1 (https=)
JP (1) JP6665201B2 (https=)
KR (1) KR102559190B1 (https=)
CN (1) CN107743489B (https=)
AU (1) AU2016241568B2 (https=)
BR (1) BR112017020131B1 (https=)
CA (1) CA2978828A1 (https=)
DK (1) DK3277687T3 (https=)
EA (1) EA032826B1 (https=)
ES (1) ES2765642T3 (https=)
HR (1) HRP20192195T1 (https=)
HU (1) HUE047822T2 (https=)
MX (1) MX2017011423A (https=)
PL (2) PL236355B1 (https=)
PT (1) PT3277687T (https=)
SI (1) SI3277687T1 (https=)
WO (1) WO2016157091A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI885039B (zh) 2020-01-13 2025-06-01 美商邊際分析公司 經取代吡唑并嘧啶及其用途
WO2022064459A1 (en) * 2020-09-28 2022-03-31 1ST Biotherapeutics, Inc. Indazoles as hematopoietic progenitor kinase 1 (hpk1) inhibitors and methods of using same
US20240018151A1 (en) * 2020-10-19 2024-01-18 Tme Therapeutics Llc Novel inhibitors of pikfyve and methods using same
CN114957261B (zh) * 2022-05-17 2023-06-23 重庆文理学院 一种具有抗头颈癌作用的化合物及其制备方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU713673B2 (en) * 1996-02-07 1999-12-09 Neurocrine Biosciences Inc. Pyrazolopyrimidines as crf receptor antagonists
CN1918172B (zh) 2003-12-23 2011-09-14 活跃生物工艺学公司 利福霉素类似物及其用途
BRPI0607927A2 (pt) * 2005-02-11 2009-10-20 Hoffmann La Roche derivados de pirazol-pirimidina
HRP20100516T1 (hr) * 2006-09-20 2010-10-31 Eli Lilly And Company Tiazolpirazolopirimidini kao antagonisti receptora crf1
US20110230464A1 (en) 2007-10-26 2011-09-22 Paul Goldsmith Purine derivatives useful as p13 kinase inhibitors
MX2010009416A (es) 2008-02-26 2010-09-24 Novartis Ag Compuestos heterociclicos como inhibidores de cxcr2.
CA2721851A1 (en) * 2008-05-30 2009-12-03 Genentech, Inc. Purine pi3k inhibitor compounds and methods of use
WO2010037765A2 (en) * 2008-10-03 2010-04-08 Merck Serono S.A. 4-morpholino-pyrido[3,2-d]pyrimidines
JP5578490B2 (ja) * 2008-12-26 2014-08-27 味の素株式会社 ピラゾロピリミジン化合物
BRPI1014572B8 (pt) * 2009-04-16 2022-07-19 Fundacion Centro Nac De Investigaciones Oncologicas Carlos Iii Imidazopirazinas para uso como inibidores de cinase
BRPI1009022A2 (pt) 2009-05-27 2016-03-08 Hoffmann La Roche "composto, composição farmacêutica, processo para produzir uma composição farmacêutica, uso de um composto, método para tratamento de uma doença ou transtorno e kit"
US8158625B2 (en) * 2009-05-27 2012-04-17 Genentech, Inc. Bicyclic indole-pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use
GB0912745D0 (en) 2009-07-22 2009-08-26 Wolfson Microelectronics Plc Improvements relating to DC-DC converters
EP2539337A1 (en) 2010-02-22 2013-01-02 F. Hoffmann-La Roche AG Pyrido[3,2-d]pyrimidine pi3k delta inhibitor compounds and methods of use
US8969364B2 (en) 2010-03-04 2015-03-03 Merck Sharp & Dohme Corp. Inhibitors of catechol O-methyl transferase and their use in the treatment of psychotic disorders
WO2013028263A1 (en) * 2011-08-24 2013-02-28 Glaxosmithkline Llc Pyrazolopyrimidine derivatives as pi3 kinase inhibitors

Also Published As

Publication number Publication date
BR112017020131A2 (pt) 2018-05-29
KR102559190B1 (ko) 2023-07-25
JP2018510192A (ja) 2018-04-12
ES2765642T3 (es) 2020-06-10
HUE047822T2 (hu) 2020-05-28
EP3277687B1 (en) 2019-10-30
CN107743489B (zh) 2021-05-04
EA032826B1 (ru) 2019-07-31
DK3277687T3 (da) 2019-12-16
PL411864A1 (pl) 2016-10-10
CN107743489A (zh) 2018-02-27
EP3277687A1 (en) 2018-02-07
EA201792087A1 (ru) 2018-03-30
JP6665201B2 (ja) 2020-03-13
MX2017011423A (es) 2018-05-17
SI3277687T1 (sl) 2020-02-28
PL236355B1 (pl) 2021-01-11
PL3277687T3 (pl) 2020-09-21
HRP20192195T1 (hr) 2020-03-06
PT3277687T (pt) 2020-01-10
US20180111939A1 (en) 2018-04-26
BR112017020131B1 (pt) 2023-02-28
KR20170132275A (ko) 2017-12-01
US10138247B2 (en) 2018-11-27
AU2016241568B2 (en) 2019-09-26
AU2016241568A1 (en) 2017-10-19
WO2016157091A1 (en) 2016-10-06

Similar Documents

Publication Publication Date Title
AU2022200741B2 (en) Aminothiazole compounds as c-Kit inhibitors
CN108699062B (zh) 四氢吡喃基氨基-吡咯并嘧啶酮及其使用方法
US20240270753A1 (en) Heterocyclic compound for inhibiting shp2 activity, preparation method therefor and use thereof
JP5501355B2 (ja) 置換アルキルピリミジン−４−オン誘導体
US11858897B2 (en) Substituted 6,11-dihydro-5H-benzo[b]carbazoles as inhibitors of ALK and SRPK
JP5583698B2 (ja) プロテインキナーゼａｂｌおよびｓｒｃの阻害剤としてのアザインドール誘導体
WO2005085252A1 (en) Imidazo ‘1,2-a’ pyrazine compounds which interact with protein kinases
CA3241069A1 (en) Macrocyclic btk inhibitors
CA2978828A1 (en) 7-(morpholin-4-yl)pyrazole[1,5-a]pyrimidine derivatives which are useful for the treatment of immune or inflammatory diseases or cancer
CN114685520B (zh) 三并环化合物及其药物组合物和应用
CN110357905B (zh) 作为蛋白激酶抑制剂的大环类衍生物及其制备方法和用途
WO2023020209A1 (zh) 含2-芳杂环取代的脲类化合物、其制备方法和用途
JP2021512942A (ja) トリアゾール、イミダゾールおよびピロール縮合ピペラジン誘導体、およびｍＧｌｕ５受容体のモジュレータとしてのそれらの使用
JP2025522978A (ja) がんの処置のためのホスホリルプリノン化合物
HK1214244A1 (zh) 咪唑并吡啶衍生物
CN117088887A (zh) Shp2抑制剂及其用途
EP4626880A1 (en) Compounds for modulating hur (elavl1)
JPWO2000076980A1 (ja) 新規な含窒素複素環誘導体又はその塩

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210322

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20241002

N11 Application terminated

Free format text: ST27 STATUS EVENT CODE: T-6-6-N10-N11-N106 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION NOT REINSTATED BY DEADLINE

Effective date: 20251002

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251229

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260105